Branded Drug Prices Increase To Offset Spending Slowdown

BMI View: Despite the recent US healthcare overhaul increasing access to medical services, President Barack Obama intends to slow the growth rate of the healthcare budget. In light of this scenario, BMI believes that greater demand for cheaper generic drugs will account for the highest market growth rates in the pharmaceutical sector. Despite the fact that branded drugs will see profit margins increasing, sales are expected to show only modest growth over the next few years. Moreover, greater demand for technologies that improve operational efficiencies and reduce patient care costs represent significant market growth opportunities for the medical devices and

To read the full article, please choose one of the following options: